Navigation Links
Halozyme Therapeutics Reports Third Quarter 2011 Financial Results
Date:11/7/2011

cer
(858) 704-8272
kgustafson@halozyme.comHalozyme Therapeutics, Inc.Condensed Consolidated Statements of Operations(unaudited)Three Months EndedNine Months EndedSeptember 30, September 30, 2011201020112010REVENUES:Product sales

$  1,156,903$
98,100$  1,487,822$
95,440Revenues under collaborative agreements

21,785,5253,298,40752,187,4479,356,151Total revenues

22,942,4283,396,50753,675,26910,051,591OPERATING EXPENSES:Cost of product sales

11,7237,214201,67596,413Research and development

13,514,35212,448,86542,647,26535,840,475Selling, general and administrative

4,263,5203,374,06912,237,15210,488,568Total operating expenses

17,789,59515,830,14855,086,09246,425,456OPERATING INCOME (LOSS)

5,152,833(12,433,641)(1,410,823)(36,373,865)Interest and other income, net

12,36024,06556,58625,889NET INCOME (LOSS)

$  5,165,193$ (12,409,576)$ (1,354,237)$ (36,347,976)Net income (loss) per share:Basic

$
.05$
(0.13)$
(0.01)$
(0.39)Diluted

$
.05$
(0.13)$
(0.01)$
(0.39)Shares used in computing net income (loss)  per share:Basic

103,223,35293,626,893102,282,90492,342,665Diluted

105,009,18993,626,893102,282,90492,342,665Halozyme Therapeutics, Inc.Condensed Consolidated Balance SheetsSeptember 30, December 31,20112010(unaudited)ASSETSCurrent assets:Cash and cash equivalents$
,329,358$   83,255,848Accounts receivable6,237,9042,328,268Inventory103,443193,422Prepaid expenses and other assets4,297,8143,720,896Total current assets76,968,51989,498,434Property and equipment, net1,274,7531,846,899Total Assets$
78,243,272$   91,345,333LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable$
,219,905$
3,820,368Accrued expenses8,864,7058,605,569Deferred revenue3,707,7952,917,129Total current liabilities13,792,40515,343,066Deferred revenue, net of current portion36,6
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma
2. Halozyme Begins Clinical Trial with HTI-501 in Women with Edematous Fibrosclerotic Panniculopathy
3. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
4. Halozyme Therapeutics to Present Data on its Ultrafast Insulin Programs at the Upcoming American Diabetes Association 71st Scientific Sessions
5. Halozyme Therapeutics to Present at the Jefferies 2011 Global Healthcare Conference on June 9
6. Halozyme Therapeutics Reports First Quarter 2011 Financial Results
7. Halozymes Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps
8. Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab)
9. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
10. Halozyme Receives $5.5 Million Payment From Baxter
11. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... An analysis by Replikins, Ltd. of Pubmed ... CoV virus strains has revealed extensive conservation and ... conservation and sharing of specific Replikin gene structures has ... as it did for the H5N1 influenza vaccine and ... been found to be effective (1,2). ...
(Date:8/26/2014)... Israel , August 26, 2014 ... 3DM, supports NHS hospitals with surgery validation using its Stratasys ... - Performing surgery on 3D printed models prior to ... and provides an effective aid for both patient and surgeon ... SSYS ), a global leader of 3D printing and ...
(Date:8/26/2014)... Aug. 26, 2014 Technology Applications International ... (NUUU) has two (2) wholly- owned subsidiaries, Renuell ... harness scientifically advanced technology to provide advanced solutions ... Renuell Int,l, Inc. is launching its REJUVEL ... products that is made possible because of its ...
(Date:8/26/2014)... 2014 Trovagene, Inc. (NASDAQ:  TROV) presented ... Moving Assays to the Clinic with an ... Cell Free Tumor DNA in Urine." In this ... Precision Cancer Monitoring (PCM) platform and results from ... detection of tumor DNA mutations from urine samples ...
Breaking Biology Technology:Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 2Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 3Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 4Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 5Technology Applications International Corporation, Trading Symbol NUUU now trading on NASDAQ's Over the Counter Bulletin Board (OTC BB) 2Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 2Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 3Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 4
... -. Actavis Group, the,international generic pharmaceuticals company, has ... Food & Drug,Administration. Distribution of the product will ... equivalent to Pfizer,s,Camptosar(R) will be available in 40 ... and is,used in the treatment of patients with ...
... CryoCath,s Cryoablation System, SAN DIEGO, Feb. 28 ... focused on the treatment of cardiac,arrhythmias, announced today ... the,United States International Trade Commission (ITC) alleging that ... by infringing on,several CryoCor patents with its cryoablation ...
... Johnson, Jr. Resigns as President and Chief Executive ... Opportunities, HAYWARD, Calif., Feb. 28 Kosan ... Robert G. Johnson, Jr.,M.D., Ph.D., has resigned as ... Kosan,s Board of Directors. Helen S. Kim, who ...
Cached Biology Technology:Actavis Receives Approval for Irinotecan Hydrochloride Injection; Extends US Portfolio with First Injectable Product 2CryoCor Requests International Trade Commission Investigation Into CryoCath for Patent Infringement 2CryoCor Requests International Trade Commission Investigation Into CryoCath for Patent Infringement 3Kosan Announces Senior Management Changes and Clinical Portfolio Priorities 2Kosan Announces Senior Management Changes and Clinical Portfolio Priorities 3Kosan Announces Senior Management Changes and Clinical Portfolio Priorities 4Kosan Announces Senior Management Changes and Clinical Portfolio Priorities 5Kosan Announces Senior Management Changes and Clinical Portfolio Priorities 6Kosan Announces Senior Management Changes and Clinical Portfolio Priorities 7Kosan Announces Senior Management Changes and Clinical Portfolio Priorities 8
(Date:8/27/2014)... have found that century-old museum specimens hold clues to how ... can weaken and kill trees and the news is ... increase on oak and maple trees in warmer urban areas, ... with global warming," says Dr. Elsa Youngsteadt, a research associate ... the work. , "More scale insects would be a problem, ...
(Date:8/26/2014)... pressure from policymakers, consumers, and suppliers has prompted ... reducing the pollutants they emit from their smokestacks ... must also assess environmental performance at every step ... materials to the use and recycling of their ... the discipline known as life cycle engineering, which ...
(Date:8/26/2014)... and social problems such as global warming and ... does the burden fall on our failure as ... a new study in the Journal of ... for solving global problems from governments to consumers ... "When businesses convince politicians to encourage responsible consumption ...
Breaking Biology News(10 mins):Museum specimens, modern cities show how an insect pest will respond to climate change 2Yale journal explores advances in sustainable manufacturing 2An inconvenient truth: Does responsible consumption benefit corporations more than society? 2
... immobile organisms like plants cope when faced with alterations ... in light of new environmental conditions brought on by ... published in the Nov. 16 issue of the journal ... as their maternal plant performed almost 3 times better ...
... million-year-old dinosaur that had a mouth that worked like ... translucent skull bones will be unveiled Thursday, Nov. 15, ... Sahara by National Geographic Explorer-in-Residence Paul Sereno, paleontologist and ... a plant eater known as Nigersaurus taqueti. Originally named ...
... Cancer Foundation today announced they will collectively donate $6 ... Amplification of Research), an innovative research initiative focused on ... to treat prostate cancer, as well as other research ... the first phase of research and development with a ...
Cached Biology News:Evolutionary biology research on plant shows significance of maternal effects 2Dinosaur from Sahara ate like a 'mesozoic cow' 2Dinosaur from Sahara ate like a 'mesozoic cow' 3Safeway Inc. and PCF to fund landmark prostate cancer research collaboration 2Safeway Inc. and PCF to fund landmark prostate cancer research collaboration 3Safeway Inc. and PCF to fund landmark prostate cancer research collaboration 4
... cm, is used for vertical slab gel electrophoresis ... The cell is supplied without spacers and combs. ... gaskets, lower buffer chamber, lid with cables, 2 ... buffer dam, casting stand with gaskets, leveling bubble, ...
CleanCut agarose is used to prepare genomic DNA plugs for use in pulsed field gel electrophoresis (PFGE) applications. Supplied as a 12 ml solution of 2% agarose....
...
... This system uses the Adept CE 4100 ... CE 4200 dual wavelength detector for ... PowerStream data processing software and interface unit, CE ... Windows XP may also be used with Windows ...
Biology Products: